Search

Author/Creator Kaufman, Howard L

2. Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. (6th November 2014)

Authors:
Kaufman, Howard L; Andtbacka, Robert HI; Collichio, Frances A; Wolf, Michael; Li, Ai; Shilkrut, Mark; Puzanov, Igor; Ross, Merrick
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Issue 10 (October 2016)

Authors:
Kaufman, Howard L; Russell, Jeffery; Hamid, Omid; Bhatia, Shailender; Terheyden, Patrick; D'Angelo, Sandra P; Shih, Kent C; Lebbé, Céleste; Linette, Gerald P; Milella, Michele; Brownell, Isaac; Lewis, Karl D; Lorch, Jochen H; Chin, Kevin; Mahnke, Lisa; von Heydebreck, Anja; Cuillerot, Jean-Marie;...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 10(2016:Oct.)
Page Start:
1374
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Issue 3 (23rd December 2020)

Authors:
Seethapathy, Harish; Lee, Meghan D; Strohbehn, Ian A; Efe, Orhan; Rusibamayila, Nifasha; Chute, Donald F; Colvin, Robert B; Rosales, Ivy A; Fadden, Riley M; Reynolds, Kerry L; Sullivan, Ryan J; Kaufman, Howard L; Jhaveri, Kenar D; Sise, Meghan E
Journal:
Nephrology dialysis transplantation
Issue:
Volume 37:Issue 3(2022)
Page Start:
507
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗